Science
Scholarly Articles (2015-2022)
Defects in fatty acid amide hydrolase 2 in a male with neurologic and -sychiatric symptoms (Canada/ USA) (full – 2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423390/
Increased Cortical Inhibition in Autism-Linked Neuroligin-3R451C Mice Is Due in Part to Loss of Endocannabinoid Signaling. (USA) (full – 2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140638
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy) (full – 2015) http://www.pnas.org/content/112/45/14084.full
Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. (USA) (full – 2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318349/
Endocannabinoid Signaling in Autism. (Italy/ UK) (full – 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604173/
β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling (USA/ Japan) (full – 2015) http://www.cell.com/cell/fulltext/S0092-8674(15)00826-0
The basolateral amygdala γ-aminobutyric acidergic system in health and disease (USA) (full – 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837071/
Endocannabinoid signaling mediates oxytocin-driven social reward. (USA/ Spain/ Italy)
(full – 2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653148/
Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s
Chorea, Alzheimer’s Disease, and Others. (Spain) (download – 2015) http://cannabismedicinal.com.ar/images/documentos/Investigacion/ChapterPertwee_2015.pdf
Endocannabinoids and Mental Disorders. (Italy) (partial preview – 2015) https://books.google.com/books?hl=en&lr=&id=QwihCgAAQBAJ&oi=fnd&pg=PA260&ots=FMJszxDVrw&sig=am4Ix9Tha8igC52J71rUp_ZscFA#v=onepage&q&f=false
p21-activated kinase 1 restricts tonic endocannabinoid signaling in the hippocampus (Canada / China) (full – 2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907698/
Endocannabinoid signaling in social functioning: an RDoC perspective. (USA) (full – 2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. (Italy) (full – 2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016182a.html
Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder (USA) (full – 2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044872/
Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. (Canada/ USA) (full – 2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461973/
Functions of synapse adhesion molecules neurexin/neurexins and neurodevelopmental disorders. (Japan) (link to PDF – 2016) https://www.researchgate.net/publication/308491092_Functions_of_synapse_adhesion_molecules_neurexinneurexins_and_neurodevelopmental_disorders
Involvement of TRPV1 in the Olfactory Bulb in Rimonabant-Induced Olfactory Discrimination Deficit. (China) (download – 2016) https://pdfs.semanticscholar.org/eedb/33ecd19175e45af894a38e9db0da6a724c7d.pdf
Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. (Ireland) (abst – 2016) http://www.sciencedirect.com/science/article/pii/S1043661816308660
Cannabinoids in Pediatrics. (USA) (full – 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/
Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. (Italy/ USA) (full – 2017) http://www.mdpi.com/1422-0067/18/7/1425/htm
Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention. (Saudi Arabia) (full – 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535348/
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. (Italy) (full – 2017) http://www.mdpi.com/1422-0067/18/9/1916/htm
Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. (USA) (full – 2017) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187926
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality? (France) (full – 2017) https://www.frontiersin.org/articles/10.3389/fnsyn.2017.00015/full
Synaptic functions of endocannabinoid signaling in health and disease (USA/ France/ Italy) (full – 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662005/
Treating a novel plasticity defect rescues episodic memory in Fragile X model mice (USA) (full – 2017) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951717/
Chronic Inflammatory Pain Impairs mGluR5-Mediated Depolarization-Induced Suppression of Excitation in the Anterior Cingulate Cortex. (China) (full -2017) https://academic.oup.com/cercor/article/28/6/2118/3829385
The Neurobiological Bases of Autism Spectrum Disorders The R451C-Neuroligin 3 mutation hampers the expression of long-term synaptic depression in the dorsal striatum (Italy) (abst – 2017) https://www.semanticscholar.org/paper/The-neurobiological-bases-of-autism-spectrum-the-3-MartellaMeringolo/c86e1fc5893fb01ccf99a45a219ab0b93aefa2f5
Plasma anandamide concentrations are lower in children with autism spectrum disorder (USA) (full – 2018) https://molecularautism.biomedcentral.com/articles/10.1186/s13229-018-0203-y
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. (Italy) (full – 2018) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871676/
Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3R451C Mouse Model of Autism. (Australia/ New Zealand) (full – 2018) https://www.frontiersin.org/articles/10.3389/fncel.2018.00234/full
Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders. (China/ Russia/ USA/ Germany) (full – 2018) https://www.nature.com/articles/s41380-018-0200-8
Sex specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling. (Italy) (full – 2018) https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14435
Role of Striatal Direct Pathway 2-Arachidonoylglycerol Signaling in Sociability and Repetitive Behavior. (USA) (full – 2018) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023784/
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study. (Israel) (link to PDF – 2018) tikunolamusa.com
Relationships between substance abuse/dependence and psychiatric disorders based on polygenic scores. (Spain) (link to PDF – 2018) https://www.semanticscholar.org/paper/Associations-between-Polygenic-Risk-for-Psychiatric-CareyAgrawal/7efd0879f4a8da6a6043f52cdf2dcb1dbe4958b7
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder (Israel) (click “drcannabiscombr” for download – 2018) https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Cannabidiol+as+a+suggested+candidate+for+treatment+of+autism+spectrum+disorder&btnG
Cannabinoids: just like any other medication? (UK) (article – 2018) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31611-8/fulltext
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. (Iran) (abst – 2018) https://www.sciencedirect.com/science/article/abs/pii/S002239561731405X?via%3Dihub
Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies. (USA) (abst – 2018) https://www.pedneur.com/article/S0887-8994(18)30842-7/fulltext
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. (Israel) (full – 2019) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336869/
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. (UK/ USA) (full – 2019) https://www.nature.com/articles/s41386-019-0333-8
The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). (UK) (full – 2019) https://journals.sagepub.com/doi/full/10.1177/0269881119858306?url_ver=Z39.88-
2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire. (USA) (full – 2019) https://www.mdpi.com/2218-1989/9/3/42/htm
Lower circulating endocannabinoid levels in children with autism spectrum disorder (Israel) (full – 2019) https://molecularautism.biomedcentral.com/articles/10.1186/s13229-019-0256-6
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. (Italy/ UK) (full -2019) https://www.frontiersin.org/articles/10.3389/fncel.2019.00367/full
Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment. (Canada) (full – 2019) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748779/
Molecular Pathology and Pharmacological Treatment of Autism Spectrum Disorder-Like Phenotypes Using Rodent Models. (Taiwan) (full – 2019) https://www.frontiersin.org/articles/10.3389/fncel.2018.00422/full
The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism (USA) (full – 2019) https://www.frontiersin.org/articles/10.3389/fncel.2019.00424/full
Current state of evidence of cannabis utilization for treatment of autism spectrum disorders (USA) (full – 2019) https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2259-4
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use (Brazil) (full – 2019) https://www.frontiersin.org/articles/10.3389/fneur.2019.01145/full
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. (UK/ USA) (full – 2019) https://www.nature.com/articles/s41398-019-0654-8
Ethical Implications for Providers Regarding Cannabis Use in Children With Autism Spectrum Disorders. (USA) (click “aappublicationsorg” for full – 2019) https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=%22Ethical+Implications+for+Providers+Regarding+Cannabis+Use+in+Children+With+Autism+Spectrum+Disorders.%22&btnG
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. (USA) (link to PDF – 2019) https://www.researchgate.net/publication/333265797_The_Potential_Benefits_of_Palmitoylethanolamide_in_Palliation_A_Qualitative_Systematic_Review
An endocannabinoid-regulated basolateral amygdala-nucleus accumbens circuit modulates sociability. (USA) (link to PDF- 2019) https://www.jci.org/articles/view/131752
Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoid mediated synaptic dysfunction in a valproic acid-induced rat model of Autism (Taiwan -abst–2019) https://www.sciencedirect.com/science/article/pii/S0028390819302953?via%3Dihub
CB1 receptor antagonism in capuchin monkeys alters social interaction and aversive memory extinction. (Brazil/ Japan) (abst – 2019)
https://www.semanticscholar.org/paper/CB1-receptor-antagonism-in-capuchin-monkeys-alters-GonczarowskaTomaz/d3688af39451da4b7e300c8d3ebbc84d6008fe60
Role of the endocannabinoid system in neurological disorders. (China) (abst – 2019) https://www.sciencedirect.com/science/article/abs/pii/S0736574818302995?via%3Dihub
Synthetic cannabinoids and their impact on neurodevelopmental processes. (Portugal) (abst – 2019) https://onlinelibrary.wiley.com/doi/abs/10.1111/adb.12824
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment (Italy/ Sweden) (abst – 2019) https://www.sciencedirect.com/science/article/abs/pii/S0024320519302176
Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. (Israel) (abst – 2019) https://www.sciencedirect.com/science/article/pii/S0278584618304445
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission? (Italy/ Netherlands) (full – 2020) https://www.mdpi.com/1422-0067/21/3/723/htm
Medical Cannabis in Children. (Israel) (link to download – 2020) https://www.rmmj.org.il/userimages/1010/1/PublishFiles/1026Article.pdf
Medicinal Use of Cannabis in Children and Pregnant Women. (Israel) (click “researchgate” for download – 2020) https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=%22Medicinal+Use+of+Cannabis+in+Children+and+Pregnant+Women.%22&btnG
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies (Italy/Spain – full-2020) https://www.mdpi.com/2076-3425/10/9/572/htm
A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report (Canada – full–2020) https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-020-02478-7
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review (Italy – full–2020) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765232/
Safety and Efficacy of Cannabis in Autism Spectrum Disorder (USA – summary–2020) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759327/
Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. (Portugal – abst–2020) https://www.sciencedirect.com/science/article/abs/pii/S1043661820311300
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience (USA – abst–2020) https://pubmed.ncbi.nlm.nih.gov/32892960/
Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story (Italy – abst–2020) https://www.sciencedirect.com/science/article/abs/pii/S0149763420306850
Cannabinoid treatment for autism: a proof-of-concept randomized trial (Israel/USA – full–2021) https://molecularautism.biomedcentral.com/articles/10.1186/s13229-021-00420-2
Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder (China – full–2021) https://royalsocietypublishing.org/doi/10.1098/rsob.200306
Acupuncture and oxytocinergic system: The promising treatment for autism (China/USA – full–2021) https://www.degruyter.com/document/doi/10.1515/tnsci-2021-0011/html
From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders? (Brazil – full-2021) https://www.frontiersin.org/articles/10.3389/fpsyt.2021.638032/full
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence (Italy/ UK) (full – 2021) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073263/
Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious? (Italy/USA – full–2021) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037883/
Cannabis and cannabinoid use in autism spectrum disorder: a systematic review (Brazil) (full – 2021) https://web.archive.org/web/20210528113054id_/http://www.scielo.br/j/trends/a/LBmJK6d8bqr5jVK6fp3CHXt/?lang=en&format=pdf
Potential therapeutic uses of cannabinoids to treat behavioural problems in children and adolescents with developmental disorders. (Australia) (full – 2021) https://www1.racgp.org.au/ajgp/2021/june/uses-of-cannabinoids-to-treat-behavioural-problems
Cannabidiol and Neurodevelopmental Disorders in Children. (Australia) (full – 2021) https://www.frontiersin.org/articles/10.3389/fpsyt.2021.643442/full
Urinary proteome profiling for children with autism using data-independent acquisition proteomics. (China) (full – 2021) https://tp.amegroups.com/article/view/74661/html
Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. (Israel) (full – 2021) https://www.nature.com/articles/s41398-021-01612-3
Endocannabinoid System Unlocks the Puzzle of Autism Treatment via Microglia (China/ USA) (full – 2021) https://www.frontiersin.org/articles/10.3389/fpsyt.2021.734837/full
Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder. (USA) (full – 2021) https://www.liebertpub.com/doi/10.1089/can.2021.0129
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric
Disorders: Molecular Mechanisms and Targets. (Italy) (full – 2021)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124847/
Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a
propensity score-matched analysis. (UK) (full – 2021)
https://bmjopen.bmj.com/content/bmjopen/11/12/e053814.full.pdf
CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in
Turkey and reviews of the literature. (Turkey) (full – 2021)
https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-021-00108-7
Infodemiological Examination of Personal and Commercial Tweets About Cannabidiol:
Term and Sentiment Analysis. (USA) (full – 2021) https://www.jmir.org/2021/12/e27307
Communication and social interaction in the cannabinoid-type 1 receptor null mouse:
Implications for autism spectrum disorder. (France/ USA/ Italy/ Spain/ Belgium/ Germany)
(full – 2021) https://hal.archives-ouvertes.fr/hal-03393739/document
Potential of cannabinoids as treatments for autism spectrum disorders. (USA)
(click “sciencedirect” for manuscript – 2021)
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Potential+of+cannabinoids+as+treatments+for+autism+spectrum+disor
ders.&btnG=
Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α,
induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
(USA) (abst – 2021) https://onlinelibrary.wiley.com/doi/10.1002/aur.2520
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
(USA) (abst – 2021) https://www.sciencedirect.com/science/article/abs/pii/S0163725821000802
Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with
Commonly Used Medications. (USA) (abst – 2021) https://pubmed.ncbi.nlm.nih.gov/34432543/
Endocannabinoid markers in autism spectrum disorder: A scoping review of human
studies. (Canada) (abst – 2021) https://www.sciencedirect.com/science/article/abs/pii/S0165178121005515
The role of the endocannabinoid system as a therapeutic target for autism spectrum
disorder: Lessons from behavioral studies on mouse models. (France)
(abst – 2021) https://www.sciencedirect.com/science/article/abs/pii/S014976342100525X
Autism and associated disorders: cannabis as a potential therapy. (USA/ Ethiopia)
(full – 2022) https://article.imrpress.com/journal/FBE/14/1/10.31083/j.fbe1401001/1945-0508-14-1-001.pdf
Clinical Data on Canabinoids: Translational Research in the Treatment of Autism
Spectrum Disorders. (Portugal) (full – 2022) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024565/
Medicinal Cannabis in Children and Adolescents with Autism Spectrum Disorder: A
Scoping Review. (Canada) (full – 2022) https://onlinelibrary.wiley.com/doi/epdf/10.1111/cch.12909
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and controlled placebo clinical trial (Brazil) (full – 2022) http://www.trends.periodikos.com.br/article/doi/10.47626/2237-6089-2021-0396
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. (Japan/ USA) (full – 2022) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237241/
Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. (Israel) (full – 2022) https://www.nature.com/articles/s41398-022-02104-8
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry. (UK) (full – 2022) https://journals.sagepub.com/doi/10.1177/20451253221116240
Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study. (Canada) (full – 2022) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509693/
Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. (Israel) (full – 2022) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559854/
Editorial: Implications of gut-brain interactions for the effects of compounds derived from Cannabis or modulating the endocannabinoid system in physiological and pathological processes. (Italy/ USA/ Canada) (editorial – 2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632282/
The role of cannabinoids in neurodevelopmental disorders of children and adolescents (Portugal) (abst in English & Spanish – 2022) https://pubmed.ncbi.nlm.nih.gov/36169325/
Cannabidiol for the treatment of autism spectrum disorder: hope or hype? (Brazil) (abst – 2022) https://link.springer.com/article/10.1007/s00213-022-06196-4
Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder. (Jordan/ USA) (abst – 2022) https://link.springer.com/article/10.1007%2Fs10803-021-05254-8
United States Patent 6630507